GNLX: Bathi saben saham sajrone rolas wulan pungkasan genelux.com

Genelux Corporation (GNLX) relies on the monetization of viral oncolytic technologies, establishing a foundation for long-term licensing. Growth is driven by the success of the Olvi-Vec candidate in ovarian cancer therapy and the readiness to submit FDA applications. However, the current research phase entails negative operating leverage. Fundamental TTM earnings per share reflect these costs, with the metric reaching -0.89.
Genelux Corp (GNLX) - rincian metrik lan laporan keuangan

Earnings per share (EPS TTM) consolidates the annual financial result, allocating total income across all securities to identify the actual profitability of the business while filtering out market noise. By analyzing the change in per-share earnings over the last 12 months, an investor assesses how the development costs of viral cancer immunotherapy at Genelux Corporation (GNLX) correlate with the efficiency of innovation capitalization.